Navigation Links
BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year
Date:11/3/2010

FRANKLIN LAKES, N.J., Nov. 3, 2010 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.873 billion for the fourth fiscal quarter ended September 30, 2010, representing an increase of 1.0 percent from the prior-year period, or 2.9 percent on a foreign currency-neutral basis.  

For the full fiscal year ended September 30, 2010, BD reported revenues of $7.372 billion, representing an increase of 5.5 percent over the prior year, or 5.6 percent on a foreign currency-neutral basis.

The Company also plans to repurchase $1.5 billion of its common stock in 2011 and an additional $600 million in 2012.  The Company plans to fund the repurchases through ongoing cash flow and the issuance of debt.  

“We are proud of our accomplishments during 2010. We met our financial and operational goals despite the challenging macroeconomic climate facing our industry,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Our solid performance has enabled us to continue to return significant value to shareholders and also to invest in key geographic expansion, new product platforms and businesses and operational excellence programs. We have confidence in our outlook for fiscal year 2011 and remain committed to serving our customers with superior healthcare products.”

Update on the Sale of Certain Assets in the BD Medical Segment In the fourth quarter of fiscal year 2010, the Company completed the sale of the Ophthalmic Systems unit as well as the surgical blades, critical care and extended dwell catheter product platforms. The results of operations associated with the Ophthalmic Systems unit, surgical blade platform and critical care platform have been reclassified as discontinued operations for all quarters and years referred to in this release.

As illustrated on page 3 of the attached financial tables, diluted earnings per share from discontinued operations for the fourth quarter of $0.44 consisted of $0.06 from operations and $0.39 from the gain on the sale.  Diluted earnings per share for the fourth quarter of $1.68 less the $0.44 from discontinued operations resulted in diluted earnings per share from continuing operations of $1.24.  Diluted earnings per share from discontinued operations for the year of $0.59 consisted of $0.21 from operations and $0.38 from the gain on the sale.  Diluted earnings per share for the year of $5.49 less the $0.59 from discontinued operations resulted in diluted earnings per share from continuing operations of $4.90.  

Also included in the attached financial tables are the Company’s Consolidated Income Statements for the first three quarters of fiscal year 2010 and for all periods in fiscal year 2009 for reference, which reflect the reclassification change for the Ophthalmic Systems unit, surgical blade platform and critical care platform. The results of operations associated with the extended dwell catheter product platform are reported within continuing operations, as this asset group did not meet the criteria for discontinued operations.

Fourth Quarter Earnings and Analysis of the Full Fiscal Year 2010 and 2009 EarningsReported diluted earnings per share from continuing operations for the fourth quarter were $1.24, compared with $1.20 in the prior-year period, representing a 3.3 percent increase. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 1.7 percent.  

For the full fiscal year ended September 30, 2010, reported diluted earnings per share from continuing operations were $4.90, compared with $4.73 in the prior fiscal year, representing an increase of 3.6 percent. Current full fiscal year results include a previously disclosed non-cash charge of $8.9 million, or $0.04 per share from continuing operations, related to healthcare reform impacting Medicare Part D reimbursements. The prior fiscal year included a $20 million, or $0.08 per share, tax benefit related to various tax settlements in multiple jurisdictions and a litigation charge of $45 million, or $0.11 per share, which were also previously disclosed. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 3.8 percent to $4.94, compared with $4.76 adjusted diluted earnings per share in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 9.2 percent.

Segment ResultsIn the BD Medical segment, worldwide revenues for the quarter were $959 million, representing a decrease of 0.3 percent compared with the prior-year period. Revenues increased 2.1 percent on a foreign currency-neutral basis. Segment revenue growth reflected an unfavorable comparison to the prior year of 4.3 percentage points due to the sales related to the H1N1 flu pandemic in fiscal year 2009, partially offset by strong growth in the Diabetes Care business. For the twelve-month period ended September 30, 2010, BD Medical revenues increased 6.7 percent, or 6.2 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $591 million, representing an increase of 2.0 percent compared with the prior-year period, or 3.1 percent on a foreign currency-neutral basis.  Segment revenue growth was negatively impacted by 2.4 percentage points due to sales related to the flu pandemic in fiscal year 2009 in addition to lower lab testing and reduced physician office visits. For the twelve-month period ended September 30, 2010, BD Diagnostics revenues increased 4.2 percent, or 4.0 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $323 million, representing an increase of 3.5 percent compared with the prior-year period. Revenues increased 5.3 percent on a foreign currency-neutral basis, primarily driven by instrument and reagent sales in the Cell Analysis business unit. For the twelve-month period ended September 30, 2010, BD Biosciences revenues increased 4.4 percent, or 6.8 percent on a foreign currency-neutral basis.

Geographic ResultsFourth quarter revenues in the U.S. were $832 million, representing an increase of 1.4 percent compared with the prior-year period, including a negative impact of 1.8 percentage points related to the flu pandemic.  Revenues outside of the U.S. were $1.041 billion, representing an increase of 0.8 percent compared with the prior-year period, or 4.2 percent on a foreign currency-neutral basis. International revenue growth was negatively impacted by 4 percentage points due to the H1N1 flu pandemic-related sales in fiscal year 2009. Revenues reflected continuing strength in emerging markets, which was partially offset by slower growth in Europe. For the twelve-month period ended September 30, 2010, revenues in the U.S. were $3.287 billion, representing an increase of 5.0 percent compared with the prior-year period.  Revenues outside of the U.S. were $4.086 billion, representing an increase of 5.9 percent compared with the prior-year period, or 6.0 percent on a foreign currency-neutral basis.

Fiscal 2011 Outlook for Full Year The Company estimates that reported revenues for the full fiscal year 2011 will increase about 4 percent.  The Company also expects reported diluted earnings per share from continuing operations for fiscal year 2011 to be between $5.45 and $5.55, an increase of approximately 11 to 13 percent over fiscal year 2010.  Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 10 to 12 percent over adjusted diluted earnings per share from continuing operations, excluding specified item, of $4.94 for the fiscal year 2010.

Conference Call InformationA conference call regarding BD’s fourth quarter results and its expectations for the full fiscal year 2011 will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Thursday, November 4, 2010.  The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on Thursday, November 11, 2010, access code 15660232.

Non-GAAP Financial MeasuresThis news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled “Fiscal 2011 Outlook”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to:  the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.BECTON DICKINSON AND COMPANY CONSOLIDATED INCOME STATEMENTS(Unaudited; Amounts in thousands, except per share data)Three Months Ended September 30,20102009% ChangeREVENUES

$

1,873,195

$

1,854,0231.0Cost of products sold900,933890,1971.2Selling and administrative 438,139427,0082.6Research and development123,606112,8909.5TOTAL OPERATING COSTSAND EXPENSES1,462,6781,430,0952.3OPERATING INCOME410,517423,928(3.2)Interest income14,59414,4181.2Interest expense(12,278)(13,782)(10.9)Other income (expense), net1,285(3,312)NM INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES414,118421,252(1.7)Income tax provision121,065126,824(4.5)INCOME FROM CONTINUING OPERATIONS293,053294,428(0.5)INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $27,645 AND $7,684, RESPECTIVELY103,64222,792NM NET INCOME

$

396,695

$

317,22025.1EARNINGS PER SHAREBasic:Income from continuing operations

$

1.27

$

1.233.3Income from discontinued operations

$

0.45

$

0.10NM Net income (1)

$

1.71

$

1.3328.6Diluted:Income from continuing operations

$

1.24

$

1.203.3Income from discontinued operations

$

0.44

$

0.09NM Net income

$

1.68

$

1.2930.2AVERAGE SHARES OUTSTANDINGBasic231,396239,162Diluted236,316245,056NM - Not Meaningful(1) Total per share amounts may not add due to rounding Page 1BECTON DICKINSON AND COMPANYCONSOLIDATED INCOME STATEMENTS(Unaudited; Amounts in thousands, except per share data)Twelve Months Ended September 30,20102009% ChangeREVENUES

$

7,372,333

$

6,986,7225.5Cost of products sold3,543,1833,311,6767.0Selling and administrative 1,721,3561,680,7972.4Research and development430,997404,5676.5TOTAL OPERATING COSTSAND EXPENSES5,695,5365,397,0405.5OPERATING INCOME1,676,7971,589,6825.5Interest income35,12933,1486.0Interest expense(51,263)(40,389)26.9Other income (expense), net497(3,850)NM INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES1,661,1601,578,5915.2Income tax provision484,820411,24617.9INCOME FROM CONTINUING OPERATIONS1,176,3401,167,3450.8INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $40,703 AND $19,975, RESPECTIVELY141,27064,258NM NET INCOME

$

1,317,610

$

1,231,6037.0EARNINGS PER SHAREBasic:Income from continuing operations

$

5.02

$

4.853.5Income from discontinued operations

$

0.60

$

0.27NM Net income

$

5.62

$

5.129.8Diluted:Income from continuing operations

$

4.90

$

4.733.6Income from discontinued operations

$

0.59

$

0.26NM Net income

$

5.49

$

4.9910.0AVERAGE SHARES OUTSTANDINGBasic234,328240,479Diluted240,136246,798NM - Not MeaningfulPage 2Becton Dickinson and CompanySupplemental Income Statement Information - Fiscal 2010Revised for discontinued operations of certain Medical segment divestitures(Unaudited: Amounts in thousands, except per-share data)Amounts ReclassifiedPreviouslyto DiscontinuedAsReportedOperationsRevisedQuarter 1Revenues$ 1,916,774$
47,956$ 1,868,818Income from Continuing Operations$
315,978$
,885$
304,093Diluted Earnings Per Share from Continuing Operations$
.30$
.05$
.25Quarter 2Revenues$ 1,844,854$
45,445$ 1,799,409Income from Continuing Operations$
297,725$
2,691$
285,034Diluted Earnings Per Share from Continuing Operations (2)$
.24$
.05$
.18Quarter 3Revenues$ 1,878,229$
47,318$ 1,830,911Income from Continuing Operations$
306,283$
2,123$
294,160Diluted Earnings Per Share from Continuing Operations (2)$
.29$
.05$
.23Amounts Reclassified to Discontinued Operations From  OperationsGainContinuingTotalExcluding Gainon SaleTotalOperationsQuarter 4 (1)Revenues$ 1,899,548$
26,353$
-$
26,353$ 1,873,195Income$
397,445$
3,258$
91,134$
4,392$
293,053Diluted Earnings Per Share (2)$
.68$
.06$
.39$
.44$
.24Year  (1)Revenues$ 7,539,405$
7,072$
-$
7,072$ 7,372,333Income$ 1,317,431$
49,957$
91,134$
41,091$ 1,176,340Diluted Earnings Per Share$
5.49$
.21$
.38$
.59$
4.90Certain quarterly amounts may not add to the year-to-date totals due to rounding.(1) The sale of Ophthalmic Systems unit and the surgical blades product platforms was completed on July 30, 2010 and the sale of the critical care product platform was completed on September 30, 2010.  (2) Diluted Earnings Per Share may not add due to rounding.Page 3Becton Dickinson and CompanySupplemental Income Statement Information - Fiscal 2009 and 2008Revised for discontinued operations of certain Medical segment divestitures(Unaudited: Amounts in thousands, except per-share data)Amounts ReclassifiedPreviouslyto DiscontinuedAsReported OperationsRevisedFiscal 2009Revenues$ 7,160,874$
74,152$ 6,986,722Income from Continuing Operations$ 1,213,054$
45,709$ 1,167,345Diluted Earnings Per Share from Continuing Operations$
4.92$
.19$
4.73Fiscal 2008Revenues$ 7,074,942$
77,323$ 6,897,619Income from Continuing Operations$ 1,115,867$
38,113$ 1,077,754Diluted Earnings Per Share from Continuing Operations$
4.42$
.15$
4.27 Page 4BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY SEGMENT AND GEOGRAPHIC AREA(Unaudited; Amounts in thousands)Three Months Ended September 30,20102009% ChangeBD MEDICAL   United States

$

400,231

$

392,1112.1   International558,374569,677(2.0)TOTAL

$

958,605

$

961,788(0.3)BD DIAGNOSTICS   United States

$

307,721

$

305,4880.7   International283,743274,5213.4TOTAL

$

591,464

$

580,0092.0BD BIOSCIENCES   United States

$

124,009

$

123,2250.6   International199,117189,0015.4TOTAL

$

323,126

$

312,2263.5TOTAL REVENUES   United States

$

831,961

$

820,8241.4   International1,041,2341,033,1990.8TOTAL

$

1,873,195

$

1,854,0231.0Page 5BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY SEGMENT AND GEOGRAPHIC AREA(Unaudited; Amounts in thousands)Twelve Months Ended September 30,20102009% ChangeBD MEDICAL   United States

$

1,596,336

$

1,503,4716.2   International2,200,0962,053,2237.2TOTAL

$

3,796,432

$

3,556,6946.7BD DIAGNOSTICS   United States

$

1,214,288

$

1,177,5433.1   International1,104,5911,048,6765.3TOTAL

$

2,318,879

$

2,226,2194.2BD BIOSCIENCES   United States

$

475,941

$

449,1516.0   International781,081754,6583.5TOTAL

$

1,257,022

$

1,203,8094.4TOTAL REVENUES   United States

$

3,286,565

$

3,130,1655.0   International4,085,7683,856,5575.9TOTAL

$

7,372,333

$

6,986,7225.5Page 6BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended September 30,(Unaudited; Amounts in thousands)United States20102009 % Change BD MEDICAL   Medical Surgical Systems

$

256,290

$

255,1680.4   Diabetes Care98,63388,59011.3   Pharmaceutical Systems

45,30848,353(6.3)TOTAL

$

400,231

$

392,1112.1BD DIAGNOSTICS   Preanalytical Systems

$

162,024

$

156,3283.6   Diagnostic Systems145,697149,160(2.3)TOTAL

$

307,721

$

305,4880.7BD BIOSCIENCES   Cell Analysis

$

86,765

$

84,1793.1   Discovery Labware37,24439,046(4.6)TOTAL

$

124,009

$

123,2250.6TOTAL UNITED STATES

$

831,961

$

820,8241.4 Page 7 BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended September 30, (continued)(Unaudited; Amounts in thousands)International % Change 20102009 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

245,724

$

253,384(3.0)(2.2)(0.8)   Diabetes Care100,46892,0989.112.0(2.9)   Pharmaceutical Systems212,182224,195(5.4)2.8(8.2)TOTAL

$

558,374

$

569,677(2.0)2.1(4.1)BD DIAGNOSTICS   Preanalytical Systems

$

144,421

$

138,2974.47.4(3.0)   Diagnostic Systems139,322136,2242.34.1(1.8)TOTAL

$

283,743

$

274,5213.45.7(2.3)BD BIOSCIENCES   Cell Analysis

$

160,230

$

150,0556.810.4(3.6)   Discovery Labware38,88738,946(0.2)0.8(1.0)TOTAL

$

199,117

$

189,0015.48.4(3.0)TOTAL INTERNATIONAL

$

1,041,234

$

1,033,1990.84.2(3.4)Page 8BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSThree Months Ended September 30, (continued)(Unaudited; Amounts in thousands)Total % Change 20102009 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

502,014

$

508,552(1.3)(0.9)(0.4)   Diabetes Care199,101180,68810.211.7(1.5)   Pharmaceutical Systems257,490272,548(5.5)1.2(6.7)TOTAL

$

958,605

$

961,788(0.3)2.1(2.4)BD DIAGNOSTICS   Preanalytical Systems

$

306,445

$

294,6254.05.4(1.4)   Diagnostic Systems285,019285,384(0.1)0.7(0.8)TOTAL

$

591,464

$

580,0092.03.1(1.1)BD BIOSCIENCES   Cell Analysis

$

246,995

$

234,2345.47.8(2.4)   Discovery Labware76,13177,992(2.4)(1.9)(0.5)TOTAL

$

323,126

$

312,2263.55.3(1.8)TOTAL REVENUES

$

1,873,195

$

1,854,0231.02.9(1.9) Page 9BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSTwelve Months Ended September 30,(Unaudited; Amounts in thousands)United States20102009 % Change BD MEDICAL   Medical Surgical Systems

$

1,007,322

$

974,3243.4   Diabetes Care383,783351,6189.1   Pharmaceutical Systems205,231177,52915.6TOTAL

$

1,596,336

$

1,503,4716.2BD DIAGNOSTICS   Preanalytical Systems

$

627,421

$

608,7543.1   Diagnostic Systems586,867568,7893.2TOTAL

$

1,214,288

$

1,177,5433.1BD BIOSCIENCES   Cell Analysis

$

326,916

$

303,8467.6   Discovery Labware149,025145,3052.6TOTAL

$

475,941

$

449,1516.0TOTAL UNITED STATES

$

3,286,565

$

3,130,1655.0 Page 10 BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSTwelve Months Ended September 30, (continued)(Unaudited; Amounts in thousands)International% Change20102009ReportedFXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

1,002,687

$

914,9909.66.63.0   Diabetes Care401,976363,31910.69.11.5   Pharmaceutical Systems795,433774,9142.64.3(1.7)TOTAL

$

2,200,096

$

2,053,2237.26.21.0BD DIAGNOSTICS   Preanalytical Systems

$

570,386

$

534,6776.75.80.9   Diagnostic Systems534,205513,9993.93.9-TOTAL

$

1,104,591

$

1,048,6765.34.90.4BD BIOSCIENCES   Cell Analysis

$

624,322

$

600,6713.97.9(4.0)   Discovery Labware156,759153,9871.84.5(2.7)TOTAL

$

781,081

$

754,6583.57.2(3.7)TOTAL INTERNATIONAL

$

4,085,768

$

3,856,5575.96.0(0.1)Page 11BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONREVENUES BY BUSINESS SEGMENTS AND UNITSTwelve Months Ended September 30, (continued)(Unaudited; Amounts in thousands)Total % Change 20102009 Reported FXNFX ImpactBD MEDICAL   Medical Surgical Systems

$

2,010,009

$

1,889,3146.44.91.5   Diabetes Care785,759714,9379.99.10.8   Pharmaceutical Systems1,000,664952,4435.16.4(1.3)TOTAL

$

3,796,432

$

3,556,6946.76.20.5BD DIAGNOSTICS   Preanalytical Systems

$

1,197,807

$

1,143,4314.84.40.4   Diagnostic Systems1,121,0721,082,7883.53.5-TOTAL

$

2,318,879

$

2,226,2194.24.00.2BD BIOSCIENCES   Cell Analysis

$

951,238

$

904,5175.27.8(2.6)   Discovery Labware305,784299,2922.23.6(1.4)TOTAL

$

1,257,022

$

1,203,8094.46.8(2.4)TOTAL REVENUES

$

7,372,333

$

6,986,7225.55.6(0.1)Page 12BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONSAFETY REVENUES(Unaudited; Amounts in thousands)Three Months Ended September 30, % Change 20102009ReportedFXNFX ImpactTOTAL SAFETY REVENUES   United States

$

282,968

$

276,4092.42.4-   International160,396150,2706.79.2(2.5)TOTAL

$

443,364

$

426,6793.94.8(0.9)BY SEGMENT   BD Medical

$

208,822

$

204,5362.12.7(0.6)   BD Diagnostics234,542222,1435.66.7(1.1)TOTAL

$

443,364

$

426,6793.94.8(0.9)Twelve Months Ended September 30, % Change 20102009 Reported FXNFX ImpactTOTAL SAFETY REVENUES   United States

$

1,108,431

$

1,056,7974.94.9-   International621,913568,1069.58.11.4TOTAL

$

1,730,344

$

1,624,9036.56.00.5BY SEGMENT   BD Medical

$

819,084

$

761,2627.66.90.7   BD Diagnostics911,260863,6415.55.20.3TOTAL

$

1,730,344

$

1,624,9036.56.00.5Page 13BECTON DICKINSON AND COMPANYCONSOLIDATED INCOME STATEMENTS FISCAL 2010Revised for discontinued operations of certain Medical segment divestitures(Unaudited; Amounts in thousands, except per-share data)Quarter 1Quarter 2Quarter 3Quarter 3 YTDREVENUES

$

1,868,818

$

1,799,409

$

1,830,911

$

5,499,138Cost of products sold894,324864,492883,4342,642,250Selling and administrative 445,673421,076416,4681,283,217Research and development99,151100,193108,047307,391TOTAL OPERATING COSTS
AND EXPENSES1,439,1481,385,7611,407,9494,232,858OPERATING INCOME429,670413,648422,9621,266,280Interest income8,7899,6522,09420,535Interest expense(12,987)(12,913)(13,085)(38,985)Other (expense) income, net(2,354)1641,402(788)INCOME FROM CONTINUING OPERATIONS BEFOREINCOME TAXES423,118410,551413,3731,247,042Income tax provision119,025125,517119,213363,755INCOME FROM CONTINUING OPERATIONS304,093285,034294,160883,287Income from Discontinued Operations   before Income Tax16,90016,69817,08850,686Income Tax provision 4,6174,1014,34013,058INCOME FROM DISCONTINUED OPERATIONS12,28312,59712,74837,628NET INCOME

$

316,376

$

297,631

$

306,908920,915EARNINGS PER SHAREBasic:Income from continuing operations

$

1.28

$

1.21

$

1.26

$

3.75Income from discontinued operations

$

0.05

$

0.05

$

0.05

$

0.16Net income (1)

$

1.33

$

1.26

$

1.32

$

3.91Diluted:Income from continuing operations

$

1.25

$

1.18

$

1.23

$

3.66Income from discontinued operations

$

0.05

$

0.05

$

0.05

$

0.16Net income (1)

$

1.30

$

1.24

$

1.29

$

3.82AVERAGE SHARES OUTSTANDINGBasic237,360235,325233,242235,316Diluted242,965240,863238,319241,151Certain quarterly amounts may not add to the year-to-date totals due to rounding.(1) Total per share amounts may not add due to rounding.Page 14BECTON DICKINSON AND COMPANYCONSOLIDATED INCOME STATEMENTS FISCAL 2009Revised for discontinued operations of certain Medical segment divestitures(Unaudited; Amounts in thousands, except per-share data)Quarter 1Quarter 2Quarter 3Quarter 4YearREVENUES

$

1,673,148

$

1,683,142

$

1,776,409

$

1,854,023

$

6,986,722Cost of products sold775,542807,382838,555890,1973,311,676Selling and administrative 399,668430,608423,513427,0081,680,797Research and development96,35697,70097,621112,890404,567TOTAL OPERATING COSTS AND EXPENSES1,271,5661,335,6901,359,6891,430,0955,397,040OPERATING INCOME401,582347,452416,720423,9281,589,682Interest income1,6514,31212,76714,41833,148Interest expense(7,824)(7,495)(11,288)(13,782)(40,389)Other income (expense), net 9,411(5,701)(4,246)(3,312)(3,850)INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 404,820338,568413,953421,2521,578,591Income tax provision 108,21389,70286,508126,824411,246INCOME FROM CONTINUING OPERATIONS 296,607248,866327,445294,4281,167,345Income from Discontinued Operations before Income Tax20,23415,94417,57930,47684,233Income Tax provision4,7733,5213,9977,68419,975INCOME FROM DISCONTINUED OPERATIONS15,46112,42313,58222,79264,258NET INCOME

$

312,068

$

261,289

$

341,027

$

317,220

$

1,231,603EARNINGS PER SHAREBasic:Income from continuing operations

$

1.22

$

1.04

$

1.36

$

1.23

$

4.85Income from discontinued operations

$

0.06

$

0.05

$

0.06

$

0.10

$

0.27Net income (1)

$

1.29

$

1.09

$

1.42

$

1.33

$

5.12Diluted:Income from continuing operations

$

1.19

$

1.01

$

1.33

$

1.20

$

4.73Income from discontinued operations

$

0.06

$

0.05

$

0.06

$

0.09

$

0.26Net income (1)

$

1.26

$

1.06

$

1.39

$

1.29

$

4.99AVERAGE SHARES OUTSTANDINGBasic242,397240,239240,109239,162240,479Diluted248,311245,890245,696245,056246,798Certain quarterly amounts may not add to the year-to-date totals due to rounding.(1) Total per share amounts may not add due to rounding.Page  15BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONSAFETY REVENUES FISCAL 2010Revised for discontinued operations of certain Medical segment divestitures(Unaudited; Amounts in thousands)Quarter 1Quarter 2Quarter 3Quarter 3 YTDTOTAL SAFETY REVENUES   United States

$

291,815

$

263,044

$

270,604

$

825,463   International155,129148,537157,851461,517TOTAL

$

446,944

$

411,581

$

428,455

$

1,286,980BY SEGMENT   BD Medical

$

221,174

$

193,688

$

195,400

$

610,262   BD Diagnostics225,770217,893233,055676,718TOTAL

$

446,944

$

411,581

$

428,455

$

1,286,980Page  16BECTON DICKINSON AND COMPANYSUPPLEMENTAL REVENUE INFORMATIONSAFETY REVENUES FISCAL 2009Revised for discontinued operations of certain Medical segment divestitures(Unaudited; Amounts in thousands)Quarter 1Quarter 2Quarter 3Quarter 4YearTOTAL SAFETY REVENUES   United States

$

263,865

$

249,820

$

266,703

$

276,409

$

1,056,797   International133,499136,054148,283150,270568,106TOTAL

$

397,364

$

385,874

$

414,986

$

426,679

$

1,624,903BY SEGMENT   BD Medical

$

187,066

$

177,721

$

191,939

$

204,536

$

761,262   BD Diagnostics210,298208,153223,047222,143863,641TOTAL

$

397,364

$

385,874

$

414,986

$

426,679

$

1,624,903Page  17Contact:Zachary A. Nagle, Investor Relations – 201-847-5453Colleen T. White, Corporate Communications – 201-847-5369
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Telik Announces Third Quarter 2010 Financial Results
3. DURECT Corporation Announces Third Quarter 2010 Financial Results
4. Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results
5. Benchmark Electronics Announces Thailand Facility Class III Medical Device Manufacturing Capabilities
6. PharmAthene Announces Closing of $15 Million Public Offering
7. Cypin Production Announces Launch of U.S./China BioPharma Conference:
8. IDEV Technologies Announces FDA 510(k) Clearance for SUPERA VERITAS™
9. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
10. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
11. Hanger Orthopedic Group, Inc. Announces Early Tender Results of Offer to Purchase Outstanding 10-1/4% Senior Notes Due 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):